201 related articles for article (PubMed ID: 17511851)
1. Chemokine receptor CCR5 in interferon-treated multiple sclerosis.
Sellebjerg F; Kristiansen TB; Wittenhagen P; Garred P; Eugen-Olsen J; Frederiksen JL; Sørensen TL
Acta Neurol Scand; 2007 Jun; 115(6):413-8. PubMed ID: 17511851
[TBL] [Abstract][Full Text] [Related]
2. Increase in CCR5 Delta32/Delta32 genotype in multiple sclerosis.
Pulkkinen K; Luomala M; Kuusisto H; Lehtimäki T; Saarela M; Jalonen TO; Elovaara I
Acta Neurol Scand; 2004 May; 109(5):342-7. PubMed ID: 15080861
[TBL] [Abstract][Full Text] [Related]
3. CCR5-Delta32 genetic polymorphism associated with benign clinical course and magnetic resonance imaging findings in Brazilian patients with multiple sclerosis.
Kaimen-Maciel DR; Reiche EM; Brum Souza DG; Frota Comini ER; Bobroff F; Morimoto HK; Ehara Watanabe MA; Carvalho De Oliveira J; Matsuo T; Lopes J; Donadi EA
Int J Mol Med; 2007 Sep; 20(3):337-44. PubMed ID: 17671738
[TBL] [Abstract][Full Text] [Related]
4. CCR5Delta32 polymorphism effects on CCR5 expression, patterns of immunopathology and disease course in multiple sclerosis.
Kantarci OH; Morales Y; Ziemer PA; Hebrink DD; Mahad DJ; Atkinson EJ; Achenbach SJ; De Andrade M; Mack M; Ransohoff RM; Lassmann H; Bruck W; Weinshenker BG; Lucchinetti CF
J Neuroimmunol; 2005 Dec; 169(1-2):137-43. PubMed ID: 16182378
[TBL] [Abstract][Full Text] [Related]
5. Dynamic T-lymphocyte chemokine receptor expression induced by interferon-beta therapy in multiple sclerosis.
Krakauer M; Sorensen PS; Khademi M; Olsson T; Sellebjerg F
Scand J Immunol; 2006 Aug; 64(2):155-63. PubMed ID: 16867161
[TBL] [Abstract][Full Text] [Related]
6. Multiple sclerosis and optic neuritis: CCR5 and CXCR3 expressing T cells are augmented in blood and cerebrospinal fluid.
Teleshova N; Pashenkov M; Huang YM; Söderström M; Kivisäkk P; Kostulas V; Haglund M; Link H
J Neurol; 2002 Jun; 249(6):723-9. PubMed ID: 12111306
[TBL] [Abstract][Full Text] [Related]
7. The role of the CCR5 Delta32 polymorphism in abdominal aortic aneurysms.
Sandford B; Bown M; London N; Sayers R
Int J Immunogenet; 2009 Aug; 36(4):199-205. PubMed ID: 19476483
[TBL] [Abstract][Full Text] [Related]
8. 3'UTR C2370A allele of the IL-23 receptor gene is associated with relapsing-remitting multiple sclerosis.
Illes Z; Safrany E; Peterfalvi A; Magyari L; Farago B; Pozsonyi E; Rozsa C; Komoly S; Melegh B
Neurosci Lett; 2008 Jan; 431(1):36-8. PubMed ID: 18180107
[TBL] [Abstract][Full Text] [Related]
9. The chemokine receptor CCR5 Δ32 allele in natalizumab-treated multiple sclerosis.
Møller M; Søndergaard HB; Koch-Henriksen N; Sorensen PS; Sellebjerg F; Oturai AB
Acta Neurol Scand; 2014 Jan; 129(1):27-31. PubMed ID: 23668375
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenetics of MXA SNPs in interferon-beta treated multiple sclerosis patients.
Weinstock-Guttman B; Tamaño-Blanco M; Bhasi K; Zivadinov R; Ramanathan M
J Neuroimmunol; 2007 Jan; 182(1-2):236-9. PubMed ID: 17126411
[TBL] [Abstract][Full Text] [Related]
11. Memory and naïve B-cell subsets in patients with multiple sclerosis.
Niino M; Hirotani M; Miyazaki Y; Sasaki H
Neurosci Lett; 2009 Oct; 464(1):74-8. PubMed ID: 19666086
[TBL] [Abstract][Full Text] [Related]
12. Glypican 5 is an interferon-beta response gene: a replication study.
Cénit MD; Blanco-Kelly F; de las Heras V; Bartolomé M; de la Concha EG; Urcelay E; Arroyo R; Martínez A
Mult Scler; 2009 Aug; 15(8):913-7. PubMed ID: 19556317
[TBL] [Abstract][Full Text] [Related]
13. Delta32 polymorphism of the chemokine receptor CCR5 in a patient with multifocal motor neuropathy.
Trebst C; Heiken H; Schmidt RE; Windhagen A; Stangel M
Muscle Nerve; 2007 Apr; 35(4):541-2. PubMed ID: 17266130
[No Abstract] [Full Text] [Related]
14. Reduced effectiveness of long-term interferon-beta treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study.
Boz C; Oger J; Gibbs E; Grossberg SE;
Mult Scler; 2007 Nov; 13(9):1127-37. PubMed ID: 17967840
[TBL] [Abstract][Full Text] [Related]
15. Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results.
Rose JW; Burns JB; Bjorklund J; Klein J; Watt HE; Carlson NG
Neurology; 2007 Aug; 69(8):785-9. PubMed ID: 17709711
[TBL] [Abstract][Full Text] [Related]
16. Genetic association of monocyte chemoattractant protein 1 (MCP-1)-2518 polymorphism in Mexican patients with transitional cell carcinoma of the bladder.
Vázquez-Lavista LG; Lima G; Gabilondo F; Llorente L
Urology; 2009 Aug; 74(2):414-8. PubMed ID: 19646633
[TBL] [Abstract][Full Text] [Related]
17. CCR5 Delta32 polymorphism: associated with gallbladder cancer susceptibility.
Srivastava A; Pandey SN; Choudhuri G; Mittal B
Scand J Immunol; 2008 May; 67(5):516-22. PubMed ID: 18405329
[TBL] [Abstract][Full Text] [Related]
18. The chemokine receptor CCR5 genetic polymorphism and expression in rheumatoid arthritis patients.
Kohem CL; Brenol JC; Xavier RM; Bredemeier M; Brenol CV; Dedavid e Silva TL; de Castilhos Mello A; Cañedo AD; Neves AG; Chies JA
Scand J Rheumatol; 2007; 36(5):359-64. PubMed ID: 17963165
[TBL] [Abstract][Full Text] [Related]
19. The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis.
Koch-Henriksen N; Sorensen PS; Bendtzen K; Flachs EM
Mult Scler; 2009 May; 15(5):601-5. PubMed ID: 19299439
[TBL] [Abstract][Full Text] [Related]
20. CCR5-Delta32 mutation is strongly associated with primary sclerosing cholangitis.
Eri R; Jonsson JR; Pandeya N; Purdie DM; Clouston AD; Martin N; Duffy D; Powell EE; Fawcett J; Florin TH; Radford-Smith GL
Genes Immun; 2004 Sep; 5(6):444-50. PubMed ID: 15215889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
